Alto Neuroscience annual return on equity
2024
2025
Alto Neuroscience Return on Equity (ROE) Growth & History (ANRO)
Alto Neuroscience's return on equity was −41.80% for fiscal 2025.
View full Alto Neuroscience company overviewAlto Neuroscience annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −41.80% | +112.19 pp |
| 2024 | 2024-12-31 | −153.99% | — |
Alto Neuroscience quarterly return on equity
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −11.95% | +1.54 pp |
| Q1 2026 | 2026-03-31 | −13.30% | −2.86 pp |
| Q4 2025 | 2025-12-31 | −12.32% | −2.71 pp |
| Q3 2025 | 2025-09-30 | −12.07% | −2.34 pp |
| Q2 2025 | 2025-06-30 | −13.49% | −4.89 pp |
| Q1 2025 | 2025-03-31 | −10.44% | +11.66 pp |
| Q4 2024 | 2024-12-31 | −9.61% | — |
| Q3 2024 | 2024-09-30 | −9.73% | — |
| Q2 2024 | 2024-06-30 | −8.60% | — |
| Q1 2024 | 2024-03-31 | −22.10% | — |
Alto Neuroscience return on equity trends
Between the periods ended 2024-12-31 and 2025-12-31, Alto Neuroscience's return on equity increased from −153.99% to −41.80%, a change of +112.19 percentage points. The latest reported quarter, Q2 2026, shows −11.95%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alto Neuroscience source filings ↗